

Remarks

Claims 1-14, 27-41, and 43-65 are pending. Claims 6-14, 27-41 and 43-52 have been withdrawn from consideration by the Examiner as directed to a nonelected invention. Claims 1-5 and 53-65 are under examination as they read on an isolated nucleotide sequence of SEQ ID NO:1, encoding a polypeptide of SEQ ID NO:4, vectors, host cells and methods of producing the polypeptide.

Rule 131 Declaration

The Examiner alleges that the Declaration submitted under 37 C.F.R. 1.131 on January 14, 2003 is defective because it contains alterations that are non-initialed and non-dated. The Examiner further alleges that two copies of the declaration are found, one for each inventor, and that one declaration has alterations an another does not. Applicants respectfully submit that this is due to a mistaken belief by Applicants' representative that it was acceptable for Applicant Starling to correct an error with his citizenship and address by striking through the incorrect citizenship and address and handwriting his corrections.

Submitted herewith is a Rule 131 Declaration (Appendices A and B) which is substantively the same as the Rule 131 Declaration submitted on January 14, 2003 but includes the correct citizenship and address of each applicant, and has been amended to reflect that it is being submitted in response to the outstanding Final Office Action. Both Applicants have reviewed the Rule 131 Declaration submitted herewith and signed their names thereto.

Applicants respectfully submit that this Declaration is acceptable and applicable to the outstanding grounds of rejection as set forth below.

Section 112, second paragraph, Rejections (Definiteness)

The Examiner has maintained the rejection that "hybridizes under stringent conditions" (which now appears in Claim 54) is ambiguous. The Examiner asserts that the specification

discloses merely general parameters for calculating such conditions, but that it is unclear which conditions are actually claimed. This rejection is respectfully traversed.

As stated in Applicants' Response dated December 4, 2002, pages 31-32 of the instant specification do not merely set forth general parameters, but rather specific conditions which are readily recognized by those of skill in the art to result in a clearly and readily detectable hybridization signal. For example, as set forth on page 31, lines 5 and 10, stringent salt conditions are desirably less than about 250 mM NaCl and 25 mM sodium citrate and stringent temperature conditions are at least about 42°C, respectively.

Section 112, second paragraph, does not require that each term in a claim be substituted for that which it defines. Rather, it requires that each claim be definite. In the present case, one skilled in the art may readily look to the present specification for guidance to determine the scope of "stringent conditions" within the context of the present claims in order to determine under which conditions a clear hybridization signal may be obtained. Applicants respectfully submit that it is not necessary to recite all of those conditions set forth in the instant specification in the present claims in place of "stringent conditions". As the claims are to be read in view of the teachings of the specification, it follows that if replacing "stringent conditions" with the conditions set forth in the specification is definite as required by Section 112, second paragraph, then the use of "stringent conditions" read in view of the specification must also be definite.

Accordingly, Applicants submit that withdrawal of the rejection under Section 112, second paragraph, is appropriate and is respectfully requested.

Section 101 Rejections (Utility)

The Examiner has maintained the rejection of Claim 1-5 and 53-65 under 35 U.S.C. 101 as lacking utility, alleging that the claimed invention is not supported by either a specific and/or substantial asserted utility or a well established utility, essentially for the reasons set forth in the previous Office Action dated June 5, 2002. For the reasons set forth below, this rejection is respectfully traversed.

As stated in Applicants' Response dated December 4, 2002, the standards required of the Patent Office for satisfying Section 101 utility are set forth in the Utility Examination Guidelines (Federal Register, Vol. 66, No. 6, pages 1092-1099, Friday, January 5, 2001). Particularly, in order to satisfy Section 101, the specification must set forth a (1) specific, (2) substantial and (3) credible utility for the claimed invention.

The Invention

The present invention is directed to nucleic acid molecules encoding APEX-1, polynucleotides having certain sequence identity to such nucleic acid molecules, polynucleotides which hybridize to the complement of such nucleic acid molecules, nucleic acid molecules encoding APEX-1 which are labeled with a detectable marker, vectors comprising nucleic acid molecules encoding APEX-1, and host vector systems comprising such vectors.

Specific and Substantial Utility

As set forth in the Utility Examination Guidelines, if Applicants have asserted that the claimed invention is useful for any particular practical purpose (i.e., it has a "specific and substantial utility") and the assertion would be considered credible by a person of ordinary skill in the art, then the utility requirement of Section 101 is satisfied.

The present specification clearly sets forth both specific and substantial utility for the claimed invention. For example, as pointed out by the Examiner, APEX or an agonist thereof may be administered to treat any number of known disorders, including inflammatory, cancer and immune disorders.

It is well established that nucleic acids and proteins encoded thereby, such as APEX, which are shown to be expressed in various tissues, may be biological targets for the treatment of disease states associated with such tissues. Indeed, the patent literature is replete with such examples. Accordingly, Applicants respectfully submit that the present invention clearly has specific and

substantial utility. The use of the claimed molecules as biological targets alone satisfies this requirement.

Credible Utility

With respect to the credible utility requirement, the present specification states repeatedly that the claimed invention shows homology to a well-characterized class, namely the CD2 subfamily. The Examiner states that the instant situation is directly analogous to that which was addressed in Brenner v. Manson 148, USPQ 689 (1966) (hereinafter "Brenner"). In the outstanding office action, the Examiner maintains reliance on Brenner, stating that "Congress intended that no patent be granted on a chemical compound whose sole "utility" consists of its potential role as an object of use-testing". Applicants arguments in reply are as set forth in the Response dated December 4, 2002 and hereinbelow.

Applicants respectfully submit that the Examiner's reliance on Brenner is again misplaced. To clarify, Brenner stands for the proposition that a claimed invention must have a practical utility (e.g., must not be useful solely for research purposes) and that utility is not satisfied merely by showing that a compound yielded belongs to a class of compounds which scientists are investigating for possible uses. This is not the case with the present invention.

The present invention is homologous to the CD2 subfamily, which is well-characterized as having utility with respect to leukocyte proliferation, differentiation, migration and activation, and diseases associated therewith (see, for example, "Background of the Invention" of the present application). Accordingly, Applicants are not merely investigating the claimed molecules for possible uses, but rather the claimed molecules have the specific, substantial and credible uses set forth above. Indeed, they have uses similar to those of other members of the CD2 subfamily.

The Examiner asserts that the present rejection is based on the failure to disclose sufficient properties of the protein and/or polynucleotide to support an inference of utility. Additionally, the Examiner states that members of the CD2 subfamily have divergent functions and therefore homology of a compound to members of this class does not support an inference of utility.

However, this is not the standard for Section 101 utility. Under the present law, homology to a molecule with known utility is acceptable for establishing Section 101 utility. Fujikawa v. Wattanasin, 93 F.3d 1559, 1565, 39 USPQ2d 1895, 1900 (Fed. Cir. 1996).

Even assuming, *arguendo*, that the Examiner's characterization of the claimed molecules and the CD2 subfamily is accurate, it is not the law that compounds showing homology to the claimed compounds cannot be classified in a family the members of which may have divergent functions. Applicants' burden is simply to show that the claimed compounds either have demonstrated utility or can be shown to have homology to molecules which have demonstrated utility, as in the present case. In any event, credible utility is even established by the use of the claimed compounds as molecular weight markers (specification page 45, lines 21-23).

Accordingly, as Applicants have asserted specific, substantial and credible utility of the claimed compounds, Applicants respectfully submit that withdrawal of the rejections under Section 101 is appropriate and is respectfully requested.

Section 112, first paragraph, Rejections (Enablement)

The Examiner has rejected Claims 1-5 and 53-65 under 35 U.S.C. 112, first paragraph, as not being enabled. The Examiner states that as the claimed compounds lack utility, one skilled in the art would not know how to make and use the claimed invention. This rejection is respectfully traversed.

Applicants arguments are set forth above as to why the claimed invention has utility under Section 101. Given that, one skilled in the art would readily be able to make and use the claimed compounds as set forth, for example, in the present specification. For example, the claimed compounds may be used in conventional screening assays and may be administered in therapeutically useful compositions. Regarding the Examiner's allegation that the specification fails to teach how to make any isolated nucleic acid molecule encoding APEX-1, Applicants submit that conventional amplification and cloning techniques may readily be used to generate APEX-1. An example is set forth at page 60, lines 25 et seq. of the present specification.

For these reasons, Applicants respectfully submit that withdrawal of the rejections under Section 112, first paragraph, is appropriate and is respectfully requested.

Section 112, first paragraph, Rejections (Written Description)

The Examiner has rejected Claims 1-5 and 53-65 under 35 U.S.C. 112, first paragraph, as lacking written description. The Examiner alleges that the claimed invention is directed to a genus and that there is not a representative number of species provided to support the genus. This rejection is respectfully traversed.

As stated by Applicants in the Response dated December 4, 2002 and reiterated herein, the present specification describes APEX-1 as a molecule having the amino acid sequence set forth in SEQ ID NO:4 and encoded by a nucleic acid having the sequence set forth in SEQ ID NO:1 (Figures 2A, 2B and 5). Therefore, a claim to an APEX-1 molecule is clearly described, no representative number of species need be provided. With respect to the claims directed to variants and polynucleotides which hybridize to complements of APEX-1, Applicants respectfully submit that one of skill in the art, using the extensive teachings in the present specification, would recognize Applicants to be in possession of such molecules. Such molecules are recognized as having the utility set forth with respect for APEX-1, and one of skill in the art will be capable of using the sequences set forth in the present specification to identify variations thereof which are within the scope of the present invention.

For these reasons, withdrawal of the rejection under Section 112, first paragraph, is appropriate and respectfully requested.

Section 102 Rejections

The Examiner has rejected Claims 1, 3-5 and 53-57 under 35 U.S.C. 102(a) as being anticipated by WO 99/63088 ("the '088 publication"). Applicants submitted a Rule 131 Declaration concurrently with a Response dated December 4, 2002, however, the Examiner has noted that said

Declaration is defective. Accordingly, as stated above, Applicants submit herewith a substitute Rule 131 Declaration that corrects the defects noted by the Examiner.

Accordingly, in view of this Rule 131 Declaration, Applicants submit that the '088 publication is not prior art to the present invention, and therefore respectfully submit that the rejection under Section 102(a) is obviated and withdrawal thereof is respectfully requested.

The Examiner has rejected Claims 53-55 under 35 U.S.C. 102(b) as being anticipated by Hillier et al. (GenBank Accession No. H73135) ("Hillier"). The Examiner alleges that Hillier teaches a 436 polynucleotide having 100% polynucleotide identity to the polynucleotide at positions 49-306 of the claimed SEQ ID NO:1. This rejection is respectfully traversed.

In response to this rejection, Applicants previously asserted that Hillier is not a sufficient prior art reference. The description and enabling disclosure requirements of 35 U.S.C. 112, first paragraph, have developed definition through many years of case law and are applied as the minimum qualitative level required for a reference to be effective. In re Hoeksema, 399 F.2d 269, 273, 158 USPQ 596, 600 (CCPA 1969); In re LeGrice, 301 F.2d 929, 936, 133 USPQ 365, 372 (CCPA 1962). Indeed, it is well-established that in order for a reference to serve as prior art, it must demonstrate that the claimed invention was in the possession of the public as dictated by the patent statute or case law, including containing a sufficient description of, and an enabling disclosure for, the claimed invention. The reference must contain sufficient technical information to describe the claimed invention to a person of ordinary skill in the art to which the claimed invention pertains and to enable such a person to make and use the claimed subject matter, without requiring undue experimentation. Hillier fails to satisfy these requirements.

The Examiner has addressed Applicants' arguments by citing In re Spada, stating that a chemical composition and its properties are inseparable. However, the Examiner does not address Applicants' arguments by stating how Hillier is a sufficient prior art reference (i.e., has utility and includes adequate written description and an enabling disclosure) and meets the legal requirements (stated above) necessary to be anticipatory under Section 102.

With respect to In re Spada Applicants respectfully submit that this case is not on point. The present invention does not concern a situation where a known compound is being claimed by including functional language to properties which were previously not appreciated. In such a case the claimed compound is anticipated by the known compound as the known compound necessarily has those same properties. However, the known compound must have utility, be described and enabled in order to anticipate the claimed invention. In the present case, Hillier merely sets forth a sequence of no known utility, for which there is no written description of the sequence and for which no enabling disclosure is provided.

Accordingly, Hillier is nothing more than a sequence of nucleotide bases about which nothing is known. It is no more relevant than would be a randomly computer-generated sequence of nucleotide bases that coincidentally have the same sequence as the claimed invention.

For these reasons, Applicants respectfully submit that withdrawal of the rejections under Section 102 is appropriate and withdrawal thereof is respectfully requested.

Section 103 Rejections

The Examiner has rejected Claims 1, 56 and 58 under 35 U.S.C. 103(a) as unpatentable over the '088 publication in view of Adams et al. for the same reasons set forth in the Office Action dated June 5, 2002. This rejection is respectfully traversed.

In view of the corrected Rule 131 Declaration submitted herewith, the '088 publication is not prior art to the present invention. Accordingly, it cannot be combined with any other reference in making a rejection under Section 103. For this reason, Applicants respectfully submit that this rejection under Section 103 is obviated and withdrawal thereof is respectfully requested.

The Examiner has rejected Claims 59-60 under 35 U.S.C. 103(a) as unpatentable over the '088 publication in view of U.S. Patent No. 6,134,002 for the same reasons set forth in the Office Action dated June 5, 2002. This rejection is respectfully traversed.

In view of the corrected Rule 131 Declaration submitted herewith, the '088 publication is not prior art to the present invention. Accordingly, it cannot be combined with any other reference in

making a rejection under Section 103. For this reason, Applicants respectfully submit that this rejection under Section 103 is obviated and withdrawal thereof is respectfully requested.

The Examiner has rejected Claims 61-64 and 65 under 35 U.S.C. 103(a) as unpatentable over the '088 publication in view of Darnell et al. for the same reasons set forth in the Office Action dated June 5, 2002. This rejection is respectfully traversed.

In view of the corrected Rule 131 Declaration submitted herewith, the '088 publication is not prior art to the present invention. Accordingly, it cannot be combined with any other reference in making a rejection under Section 103. For this reason, Applicants respectfully submit that this rejection under Section 103 is obviated and withdrawal thereof is respectfully requested.

Conclusion

In view of the remarks made herein, Applicants respectfully submit that the claims are in condition for allowance and favorable action is, therefore, respectfully requested.


Please direct any questions concerning this Response or any aspect of this case to the undersigned attorney.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3218

Date: August 20, 2003

Respectfully submitted,


Keith R. Lange
Attorney for Applicants
Reg. No. 44,201



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF
STARLING ET AL.
APPLICATION NO: 09/745,605
FILED: DECEMBER 22, 2000

Art Unit: 1644
Examiner: Haddad, Maher M.

FOR: NOVEL IMMUNOGLOBULIN SUPERFAMILY MEMBERS OF APEX-
1, APEX-2 AND APEX-3 AND USES THEREOF

Assistant Commissioner for Patents
Washington, D.C. 20231

**DECLARATION OF PRIOR INVENTION IN
THE UNITED STATES TO OVERCOME A REFERENCE UNDER 37 C.F.R. § 1.131**

Sir:

1. We, Gary C. Starling and Joshua N. Finger, respectively citizens of New Zealand and the United States, residing respectively at 52 James Vincent Drive, Clinton, CT 06413 and 538 Via Dell Caballo, San Marcos, CA 92078 are joint inventors of the above-identified application.
2. At the time of the invention thereof we were working for Bristol-Myers Squibb Company, assignee of the present application. We submit this declaration to establish completion of the invention set forth in this application in the United States at a date prior to December 9, 1999, i.e. the publication date of WO 99/63088 to Baker et al. (hereinafter the '088 publication), which was cited by the Examiner in Office Actions mailed June 5, 2002 and February 25, 2003.
3. From the documents submitted herewith and as set forth hereinbelow, it can be seen that the invention was completed in the United States before December 9, 1999, the publication date of the '088 publication. Completion of the invention prior to December 9, 1999 is shown by

conception and actual reduction to practice of the invention as evidenced by the cloning and sequencing of the APEX-1 gene (hereinafter "APEX-1"), which is also referred to in Exhibit A as DCS4.

4. To establish conception and reduction to practice, i.e. completion of the Invention at a date prior to December 9, 1999, the following documents are submitted as evidence:

a. Bristol-Myers Squibb Notebook No. 42973 assigned and completed prior to December 9, 1999 (Exhibit A), pages 42973-103 through 42973-106, 42973-112 through 42973-114, 42973-127 through 42973-129 and page 42973-158. These pages show the full-length cloning of APEX-1 and set forth the nucleotide and amino acid sequences of APEX-1, which correspond to SEQ ID NOS. 1 and 4, respectively, in the present application. The full length cDNA sequence and amino acid translation of APEX-1 is shown on page 42973-158. These notebook records evidence conception and actual reduction to practice of the complete invention prior to December 9, 1999.

5. The materials submitted herewith establish that the Invention as claimed was completed, i.e. conceived and reduced to practice, at a date prior to December 9, 1999, the publication date of the '088 publication.

6. This declaration is submitted in a response to a Final Office Action dated February 25, 2003 and is therefore believed to be timely filed.

7. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

DATED: _____


Gary C. Starling

DATED: 08-18-03



Joshua N. Finger

BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE



BRISTOL-MYERS SQUIBB

NOTEBOOK N^o 42973

Assigned to Joshua N. Fungie

Department Name _____

Department Number _____

Date Assigned . . . _____

Date Completed _____

Pages Completed from 001 to 200

Continued from Notebook Number _____

Continued in Notebook Number _____

This notebook cannot be transferred to another person

TABLE OF CONTENTS

PROJECT OR EXPERIMENT NO.	PRODUCT OR SUBSTANCE	STUDY PERFORMED OR OBJECTIVE	P
	Construction of Dendrite substrate plate		0
	Hybridization of Southern		09
	Colonies for Streptococcus - MNIS		0
	"		0
	cDNA synthesis		0
	Adoptive hybridization		09
	Dendrite clones		09
	"		09
	"		09
	Dendrite adoption hybridization		09
	"		10
	"		1
	BLANK		1
DCS4 (Apex 1)	DCS4 (clone #4) and Clone # B2 isolation		10
	"		1
	"		10
	BLANK Southern blot		10
	BLANK		10
	BLANK		10
	RNA isolation, THP1, NIH3T3, BJAB		1
	Northern hybrid of cell lines		1
	"		11
	DCS4 3'-RACE		1
	"		1
	"		1
	Northern blot of cell lines		1
	DCS4 3'-RACE		1
	"		1
	DCS4 northern analysis - MNIS		1

PROJECT OR EXPERIMENT NO	PRODUCT OR SUBSTANCE	STUDY PERFORMANCE OR OBJECTIVE	PAGES
	DCS4 MTN blots		119
	"		120
	DCS4 3'-RACE cloning		121
	" transformation		122
	"		123
	RT-PCR in cell lines - DCS4		124
	"		125
	"		126
	Full-length cloning DCS4		127
	RT-PCR using INF6/7 - DCS4		128
	"		129
WPT61 Library	RNA isolation from activated PBSTs (PMA)		130
	cDNA synthesis - WPT61 library		131
	"		132
	"		133
	RsaI digestion - WPT61 library		134
	"		135
	Hybridization		
	Adaptor ligation - WPT61 library		136
	"		137
	"		138
	DCS4 RT-PCR - cell lines		139
	"		140
	Ligation efficiency - WPT61 library		141
	FLDCS4 minipreps		142
	Genomic Southern		143
	DCS4 INF6/7 probe prep		144
	"		145
	Genomic PCR using primer pairs		146
	"		147

DATE _____ PROJ. NO. _____ EXPT. NO. _____
 SUBJECT Insertion of Clone #4 and Clone #82

PURPOSE: To insert the cDNA inserts from clone #4 and clone #82 from plasmid DNA for use as probes.

5

Materials and Methods


a) Clone #4 0.5 μ l
 Restrict III 0.1 μ l
 EcoRI 1 μ l
 dH₂O 3 μ l
 10 μ l

10

b) Clone #82 19 μ l
 Restrict III 3 μ l
 PstI 1.5 μ l
 HindIII 1.5 μ l
 dH₂O 5.0 μ l
 30.0 μ l

15

20

RESULTS:

Lane 1: No Marker
 Lane 2: Clone #4
 Lane 3: ~~Blank~~ BLANK LANE
 Lane 4: BLANK LANE
 Lane 5: Clone #82
 Lane 6: Clone #82

25

30

Discussion Clone #4 must have a mutated EcoRI site, cut again with HindIII and PstI. Go ahead and isolate clone #82 insert and analyze.

35

END

SIGNED

CROSS REFERENCES:

DATE

WITNESSED AND UNDERSTOOD BY:

DATE

J. M. Dz

H. H. H.

DATE

J. NC

EXPT NO

SUBJECT

Restrict of Clone #4 using Pst I or Hind III

Purpose To drop out insert of clone #4 using enzymes other than
EcoRI

5

Materials and Methods

10

Clone #4	1.5 μ l
Reagent II	3 μ l
Pst I	1.5 μ l
Hind III	1.5 μ l
H ₂ O	9.0 μ l
	30.0 μ l

15 Results

Lane 1 (6 marker)
Lane 2 H/P digest of DSS4
Lane 3 H/P digest of DSS4

20

25

Gel purify this fragment

2nd fragmentDiscussion

30

Just as I suspected DSS4 clone has a mutated EcoRI site as shown
by inability of EcoRI to cut out insert (42973-106, lane 2). However, Hind III and
Pst I dropped out two fragments. One fragment approximately 400 bp in size will
be gel purified and used as a probe (HP400). The 2nd fragment is approximately
80-90 bp and will go into the library.

35

END

SIGNED

DATE

WITNESSED AND
UNDERSTOOD BY:

DATE

CROSS REFERENCES:

DATE: _____

ANAL. NO. _____

EXPT. NO. _____

SUBJECT

Gel purification of clones = 2 in 1 lane = 4

Purpose To gel purify both clones isolated from Drosophila cell suspension library for use as probes in further exp.

5

Materials & Methods

See protocols from C. I. A. G. S. S. Handbook

"C. I. A. G. S. S. gel extraction kit" (C. I. A. G. S. S. Cat # 2474)

10

RESULTS

abs 260.0 nm	abs 280.0 nm	bkg abs 320.0 nm	260.0 nm 280.0 nm	280.0 nm 260.0 nm	Protein ug/ml	Nucleic Acid ug/ml
1) 0.0048	0.0027	0.0002	1.8457	0.5418	0.0025	23.1278
2) 0.0109	0.0045	-0.0006	2.2434	0.4457	0.0051	57.5225
3) 0.3912	0.2485	0.0023	1.5793	0.6332	0.2463	1944.6359
4) 0.4535	0.2929	0.0039	1.5558	0.6428	0.2890	2248.1201

$$[A] = \left(A_{260} \times (50^{25} \text{ ml}) - D \right) / 1000 = \frac{0.9}{25}$$

1) DSS4

25

$$(0.0048 \times 50^{25} \text{ ml} \times 25) / 1000 = \boxed{6^{25} \text{ ml}}$$

2) DSS02

$$(0.0109 \times 50^{25} \text{ ml} \times 25) / 1000 = \boxed{13^{25} \text{ ml}}$$

3) DSS4.1
DSS4

3) DSS4.1

$$(0.3912 \times 50^{25} \text{ ml} \times 200) / 1000 = \boxed{3.9^{25} \text{ ml}}$$

4) DSS4.2

$$(0.4535 \times 50^{25} \text{ ml} \times 200) / 1000 = \boxed{4.5^{25} \text{ ml}}$$

DISCUSSION:

35

NONE

END

SIGNED

DATE

WITNESSED AND
UNDERSTOOD BY

DATE

CROSS REFERENCES:

J. M. J. J.

H. H. H.

DATE _____ NO. _____ EXPT NO. _____
 SUBJECT South... Hybridization to confirm expression of PSSM in subline library

Purpose: To analyze the presence of PSSM in D12 cDNA, THPI cDNA and D12-THPI subtracted cDNA. To also see if other housekeeping genes such as GAPDH were subtracted out of the subtracted cDNA library.

5

Materials and Methods:

10µg of each cDNA was loaded into each well and run @ 70V for 3 hours.
 DNA was stained (see gel photo)

10

	abs 260.0 nm	abs 280.0 nm	bkg abs 320.0 nm	260.0 nm 280.0 nm	280.0 nm 260.0 nm	Protein ug/ml	Nucleic Acid ug/ml
1)	0.6093	0.4039	0.0198	1.5350	0.6515	0.3840	2947.4448
2)	0.9419	0.5982	0.0306	1.6055	0.6229	0.5676	4556.4517
3)	0.2023	0.1188	0.0005	1.7056	0.5863	0.1183	1008.9186

20

$$[C] = \frac{A_{260} - 50 \times A_{280}}{1} \times 50 = \mu g/ml$$

1) D12 cDNA

$$0.4039 \times 50 \mu g/ml \times 50 = 1.5 \mu g$$

25

2) THPI cDNA $0.9419 \times 50 \mu g/ml \times 50 = 2.4 \mu g$

3) D12-THPI subtracted cDNA $0.2023 \times 50 \mu g/ml \times 50 = 0.5 \mu g$

30

AT Lane 1 : D12 cDNA
 Lane 2 : THPI cDNA
 Lane 3 : D12-THPI subtracted cDNA

35

SIGNED

CROSS REFERENCES:

DATE

WITNESSED AND UNDERSTOOD BY

DATE

DATE: ROL NO. EXPT. NO. SUBJECT 3' RACE using DSS4 gene specific primers and RT, RT-PCR

Purpose: To amplify the remaining 3' end of the unknown DSS4 gene which shows homology to CDB4

5

Materials and Methods

a) cDNA synthesis in Dendritic, THP1 and Jurkat cells

10

poly A⁺ RNA2 μ lPrimer Q₂(JH3)1 μ ldH₂O (DEPC)9 μ l12 μ l

*Incubate @ 70°C for 10 min. Then 1 min.

15

Add to RNA/primer mix.

10x PCR Buffer

2 μ l25mM MgCl₂1 μ l

10mM dNTP's

2 μ l

20

0.1M DTT

2 μ l7 μ l

b) Incubate @ 42°C 5 min

Add 1 μ l Superscript II RT

25

Incubate @ 42°C 1 hour

Stop Rxn by 70°C incubation

Add 1 μ l RNase H

Store @ -20°C

30

continued 113

35

SIGNED

DATE

WITNESSED AND UNDERSTOOD BY:

DATE

CROSS REFERENCES:

DO NOT WRITE IN THIS MARGIN

DATE: _____ PROJ. NO. _____ EXPT. NO. _____

SUBJECT Control Gen 42973-112

combination for 42973-112

2) Primary PCR using JNF1 and Q(JNF4)

5

JNF1	1 μ l
JNF4	1 μ l
JNTPs	1 μ l
10x PCR Buffer	5 μ l
50x DNA	1 μ l
dH ₂ O	39 μ l
50x DNA Amplification	1 μ l
	50 μ l

10

15

PCR parameters:

94°C	1 min	1 cycle
94°C	1 min	25 cycles
57°C	1 min	
72°C	2 min	
72°C	2 min	1 cycle

20

3) Secondary PCR using JNF2 and Q-(JNF5)

25

JNF2	1 μ l
JNF5	1 μ l
JNTPs	1 μ l
10x PCR Buffer	5 μ l
1/50 dilution of PCR	1 μ l
dH ₂ O	39 μ l
50x Polymerase	1 μ l
	50 μ l

30

PCR parameters: Same as Primary PCR

Control to 114

35

SIGNED

John N. Jr.

DATE

WITNESSED AND UNDERSTOOD BY:

[Signature] *Hable*

DATE

CROSS REFERENCES:

RESULTS:

1 2 3 4 5 6 7 8

5

Line 1 2/1 Mure
 Line 2 Dendrite 4-1
 Line 3 THPI 4-1
 Line 4 Turret 4-1
 Line 5 Dendrite 2-5
 Line 6 THPI 2-5
 Line 7 Turret 2-5
 Line 8 SCOP Mure

10

15

DISCUSSION:

20

25

lines 2, 3, 4 are primary PIR using gpi1 (JNFI) and primary Gpi2 (JNFI).
 The same to be management posture. E. The extension time of 2 min was
 too long as Tm of ascending was low. Secondary PIR using gpi2 (JNFI)
 and primary Gpi1 (JNFI) reduced management considerably, but contains severe
 bands which may be unsatisfactory (lines 2, 6, 7). Continue with RLC
 experiments, starting with 1/50 dilution of 1st PIR, but increase Tm to
 50°C and reduce extension to 1 min (since most prominent band in
 Turret line is around 900 bp).

END

30

35

SIGNED

CROSS REFERENCES:

DATE

WITNESSED AND
UNDERSTOOD BY

DATE

DO NOT WRITE IN THIS MARGIN

DATE: PROJ: EXPT. NO.

SUBJECT Cloning of Full length DCS4 cDNA encoding 3'-UTR.

PURPOSE: To isolate the full length DCS4 cDNA of size approximately 2.6 kb from 50 μ l of PCR mixture.

5 Materials and Methods:

	<u>PCR</u>	<u>PCR parameters</u>
	EP (Ligand, μ l)	2.5 μ l
	RP (TUF4)	1.0 μ l
10	dNTPs	1.0 μ l
	10x PCR Buffer	5.0 μ l
	Alkali Phosphate	1.0 μ l
	dH ₂ O	38.5 μ l
	Deactivation cDNA	1.0 μ l
15		50.0 μ l
		94°C 1 min
		94°C 1 min
		57°C 1 min
		72°C 2.5 min
		72°C 1.0 min

Run on 50 μ l on 1.2% agarose gel.

Isolate 2.5 kb band using gel extraction kit (QIAgen)

Run on 2.0% gel; check conc.

20



- Lane 1: 10 marker
- Lane 2: 1 μ l isolated PCR fragment
- Lane 3: 3 μ l isolated PCR fragment
- Lane 4: 2 μ l of marker (1.3 kb band = 16 ng)
- Lane 5: 4 μ l of marker (1.3 kb band = 32 ng)

25

Conc. of isolated fragment is 100: = 2 ng/ μ l

Ligate fragment into TA cloning vector

30

Result: Amount of 2.5 kb fragment isolated is very low, but I ligated anyway just to try and isolate a clone.

Discussion: No discussion yet, wait until transformation.

35

SIGNED

CROSS REFERENCES:

[Signature]

DATE

WITNESSED AND UNDERSTOOD BY:

[Signature]

DATE

DATE

PROJ. NO.

EXPT. NO.

SUBJECT RT-PCR using primers TNF α and TNF β

Purpose: To optimize parameters for RT-PCR exp^t, so as to get one band at 600 bp amplified in cell lines which express the DCS gene.

5 Materials and Methods

1) 1st PCR: TNF α primer 1 μ l cDNA's used:
 TNF β primer 1 μ l a) Dendritic
 dNTP's 1 μ l b) LPS Air-T cell
 10x PCR Buffer 5 μ l c) THP1
 Adenine Polymerase 1 μ l
 dH₂O 40 μ l
 DNA 1 μ l
 50 μ l

Parameters: 94°C 1min
 94°C 1min
 61°C 1min } 30 cycles
 72°C 45sec
 72°C 1min

Lane 1: 100 bp
 Lane 2: Dendritic
 Lane 3: LPS Air-T
 Lane 4: THP1

Result 1: 600 bp band was evident, but a high background was present in reactions. To PCR with elevation of annealing temp to 63°C, in order to reduce background.

2) 2nd PCR: TNF α primer 0.5 μ l cDNA's used:
 TNF β primer 0.5 μ l a) LPS Air-T
 dNTP's 0.5 μ l b) THP1
 10x PCR Buffer 2.5 μ l
 Adenine Polymerase 0.5 μ l
 94°C 1min dH₂O 20.0 μ l
 63°C 1min cDNA 0.5 μ l
 72°C 45sec } 25 cycles 25.0 μ l
 72°C 1min

continue 42973-129

SIGNED

DATE

WITNESSED AND UNDERSTOOD BY:

DATE

CROSS REFERENCES:

DATE

PROJ.

EXPT. NO.

SUBJECT

Concord 42973-128

Result 2: Significant reduction of background, providing resolution
inhibition of non-specific binding in LPS Non-T cell and no signal
in THP1 as found earlier in page 42973-125.

5

Discussion: This experiment was done to optimize PCR parameters for
RT-PCR of immunological cell lines in order to identify
which cell types express the OCS4 transcript. As shown earlier,
LPS Non-T cells express OCS4, but THP1 does not. The
significance of lack of expression in THP1 - RNA shows the
original construction of the OCS4 cDNA is expressed differentially
between GM-CSF/IL-4 differentiated human monocytes and THP1 monocytes.
This is also proven by expression of OCS4 in dendritic cDNA.
Repeat PCR for all available cell lines.

10

15

20

25

30

35

END

SIGNED

DATE

WITNESSED AND
UNDERSTOOD BY:

DATE

CROSS REFERENCES:

DATE

31. NC.

EXPT. NC.

SUBJECT Full length cDNA sequence and a.c. translation Co-DCS4

		GGAAGTGGCTTCATTTCAGTGGCTGACTTCCAGAGAGCAAT	41
		ATGGCTGGTTCCCAACATGCCCTCACCTCATCTATCTTTGGCAGCTCACAGGGTCA	101
		<u>M A G S P T C L T L I Y I L W O L T G S</u>	20
		GCAGCCTCTGGACCCGTGAAAGAGCTGGTCCGTTCCGTTGGTGGGGCCGTGACTTTCCCC	161
		<u>A A S G P V K E L V G S V G G A V T F P</u>	40
		CTGAAGTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAACCCCTCTT	221
		<u>L K S K V K Q V D S I V W T F N T T P L</u>	60
5		GTCACCATAACAGCCAGAAGGGGGCACTATCATAGTGACCCAAATCGTAATAGGGAGAGA	281
		<u>V T I Q P E G G T I I V T Q N R N R E R</u>	80
		GTAGACTTCCCAGATGGAGGCTACTCCCTGAAGCTCAGCAAATGAAGAAGATGACTCA	341
		<u>V D F P D G G Y S L K L S K L K K</u> <u>H D S</u>	100
		GGGATCTACTATGTGGGGATATACAGCTCATCACTCCAGCAGCCCTCCACCCAGGAGTAC	401
		<u>G I Y Y V G I Y S S S L Q Q P S T Q E Y</u>	120
		GTGCTGCATGTCTACGAGCACCTGTCAAAGCCTAAAGTCACCATGGGTCTGCAGAGCAAT	461
		<u>V L H V Y E H L S K P R V T M G L Q S N</u>	140
9	10	AAGAATGGCACCTGTGTGACCAATCTGACATGCTGCATGGAACATGGGGAAGAGGATGTG	521
9		<u>K</u> <u>M G T</u> <u>C V T</u> <u>N L T</u> <u>C C M E H G E E D V</u>	160
		ATTTATACCTGGAAGGCCCTGGGGCAAGCAGCAATGAGTCCATAATGGGTCCATCCTC	581
		<u>I Y T W K A L G Q A A</u> <u>N E S H</u> <u>N G S</u> <u>I L</u>	180
		CCCATCTCCTGGAGATGGGGAGAAAGTGATATGACCTTCATCTGCGTTGCCAGGAACCTT	641
		<u>P I S W R W G E S D M T F I C V A R N P</u>	200
		GTCAGCAGAACTCTCAAGCCCCATCCTTGCCAGGAAGCTCTGTGAAGGTGCTGCTGAT	701
		<u>V S R</u> <u>N L E E</u> <u>S P I L A R K L C E G A A D</u>	220
	15	GACCCAGATTCTCCATGGTCCCTCTGTCTCCGTTGGTGGCCCTCCGCTCAGTCTC	761
		<u>D P D S S</u> <u>M V L L C L L L V P L L L S L</u>	240
		TTGTACTGGGGCTATTTCTTTGCTTTCTGAAGAGAGAGAGACAAGAAGTACATTGAA	821
		<u>F V L G L P L W F L</u> <u>K R E R Q E E Y I E</u>	260
		GAGAAGAAGAGAGTGGACATTTGTGGGAAACTCCTAACATATGCCCCCATCTCGAGAG	881
		<u>E K E R V D I C R E T P N I C P H S G E</u>	280
		AACACAGAGTACGACACAATCCCTCACACTAATAGAACAATCCTAAAGGAAGATCCAGCA	941
	20	<u>N T E Y D T I P H T M R T I L K E D P A</u>	300
		AATACGGTTTACTCCACTGTGGAAATACCGAAAAGATGGAAAATCCCCACTCACTGCTC	1001
		<u>N T V Y S T V E I P K K N E N P H S L L</u>	320
		ACGATGCCAGACACACCAAGGCTATTTGCCTATGAGAATGTTATCTAGACAGCAGTGCAC	1061
		<u>T H P D T P R L F A Y E N V I</u>	335
		TCCCTTAAGTCTCTGCTCAAAAAAACAATTCCTCGGCCCAAGAAAACATCAGAAGA	1121
		ATTCAGTATTGACTAGAAACATCAAGGAAGAATGAAGAAGTTGACTTTTTTCCAGGA	1181
		TAAATTATCTCTGATGCTTCTTTAGATTAAAGAGTTCTGTAATTCATCCACTGCTGAGAA	1241
	25	<u>ATCTCCTCAAAACCCAGAAAGTTTAACTCACTTCATCCCAAAAATGGGATTTGTAATGTCAG</u>	1301
		<u>CAAACCATAAAAAAGTGCTTAGAAGTATTCTATAGAAATGTAAATGCAAGGTCACACA</u>	1361
		<u>TATTAATGACAGCCTGTGTATTAAATGATGGCTCCAGGTCAAGTGTCTGGAGTTTCATTCC</u>	1421
		<u>ATCCCAAGGCTTGGATGTCAAGATTATACCAAGAGTCTTGCTACCAAGAGGGCAAGAAGA</u>	1481
		<u>CCAAACAGACAGACAAAGTCCAGCAGAAAGCAGATGCACCTGACAAAAATGGATGTATTAA</u>	1541
		<u>TTGGCTCTATAAACTATGTGCCAGCAGTATGCTGAGCTTACACTAATTGGTCAGACGTG</u>	1601
		<u>CTGTCTGCCCTCATGAAATTTGGCTCCAAATGAATGAAGTACTTTTCAAGCAGTTGTAGC</u>	1661
		<u>AGGCTTGACCAAGATTCCAGAGGGCCAGGTGTGGATCCACAGGACTTGAAGGTCAAAG</u>	1721
		<u>TTCAAGATGAAGAATCAGGATAGCTGACCATGTTTGGCAGATACTATAATGGAGACA</u>	1781
		<u>CAGAGTGTGCATGGCCCAAGGACAGGACCTCCAGCCAGGCTTCATTTATGCACTTGTG</u>	1841
		<u>CTGCAAAAGAAAGTCTAGGTTTTAAGGCTGTGCCAGAACCCATCCCAATAAAGAGACCG</u>	1901
	30	<u>AGTCTGAAGTCAATTGTAAATCTAGTGTAGGAGACTTGGAGTCAGGCAGTGAGACTGGT</u>	1961
		<u>GGGCCACGGGGGGCAGTGGTACTTGTAAACCTTTAAGATGGTTAATTCATTCAATAGA</u>	2021
		<u>TATTTATTAAGAACCTACTATGCGGCCCCGGCATGGTGGCTCACACCTGTAAATCCAGCAC</u>	2081
		<u>TTTGGGAGGCCAAGGTGGGTGGGTCACTGAGGTCAAGAGTTCAAGACCAGCCTGGCCAA</u>	2141
		<u>CATGGTGAACCCCCATCTCTACTAAAGATCAAAATTTGCTGAGCGTGGTGGTGTGCACCT</u>	2201
		<u>GTATCCCAGCTACTCGAGAGGGCCAAGGCATGAGAAATCGCTTGAACCTGGAGGTGAGGTTG</u>	2261
		<u>CAGTGAGCTGAGATGGCACTGCACTCCGGCCTAGGCAACGAGAGCAAACTCCAATA</u>	2321
		<u>CAACAAACAAACAAACACCTGTGCTAGGTCACTCTGGCAGTAAAGATGAACATCCCTAC</u>	2381
		<u>CAACACAGAGCTCACCATCTCTTATACTTAAGTGAAGAAATGCGGGAAGGGGAAGGGGA</u>	2441
		<u>ATGGCTGCTTTTGATATGTTCCCTGACGCATATCTTGAATGGAGACCTCCCTACCAAGTG</u>	2501
		<u>ATGAAAGTGTGAAAACTTAATAACAAATGCTTGTGGGCAAGAAATGGATTGAGGATT</u>	2561
		<u>ATCTTCTCTCAGAAAGGCATTGTGAAGGAATGAGCCAGATCTCTCTCCCTACTGCAAAA</u>	2621
	35	<u>CCCTATTGTAGTAAAAAGTCTTCTTACTATCTTAATAAACAGATATTGTGAGATTCA</u>	2681
		<u>CATAAAAAAAAAAAAAAAAA</u>	

Word Document
FLDCS4.doc

SIGNED

DATE

WITNESSED AND UNDERSTOOD BY:

DATE

CROSS REFERENCES:

APPENDIX B



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
STARLING ET AL.

Art Unit: 1644

Examiner: Haddad, Maher M.

APPLICATION NO: 09/745,605

FILED: DECEMBER 22, 2000

FOR: NOVEL IMMUNOGLOBULIN SUPERFAMILY MEMBERS OF APEX-
1, APEX-2 AND APEX-3 AND USES THEREOFAssistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

DECLARATION OF PRIOR INVENTION IN
THE UNITED STATES TO OVERCOME A REFERENCE UNDER 37 C.F.R. § 1.131 AUG 25 2003

TECH CENTER 1600/2900

Sir:

1. We, Gary C. Starling and Joshua N. Finger, respectively citizens of New Zealand and the United States, residing respectively at 52 James Vincent Drive, Clinton, CT 06413 and 538 Via Dell Caballo, San Marcos, CA 92078 are joint inventors of the above-identified application.
2. At the time of the invention thereof we were working for Bristol-Myers Squibb Company, assignee of the present application. We submit this declaration to establish completion of the invention set forth in this application in the United States at a date prior to December 9, 1999, i.e. the publication date of WO 99/63088 to Baker et al. (hereinafter the '088 publication), which was cited by the Examiner in Office Actions mailed June 5, 2002 and February 25, 2003.
3. From the documents submitted herewith and as set forth hereinbelow, it can be seen that the invention was completed in the United States before December 9, 1999, the publication date of the '088 publication. Completion of the invention prior to December 9, 1999 is shown by

conception and actual reduction to practice of the invention as evidenced by the cloning and sequencing of the APEX-1 gene (hereinafter "APEX-1"), which is also referred to in Exhibit A as DCS4.

4. To establish conception and reduction to practice, i.e. completion of the invention at a date prior to December 9, 1999, the following documents are submitted as evidence:

a. Bristol-Myers Squibb Notebook No. 42973 assigned and completed prior to December 9, 1999 (Exhibit A), pages 42973-103 through 42973-106, 42973-112 through 42973-114, 42973-127 through 42973-129 and page 42973-158. These pages show the full-length cloning of APEX-1 and set forth the nucleotide and amino acid sequences of APEX-1, which correspond to SEQ ID NOS. 1 and 4, respectively, in the present application. The full length cDNA sequence and amino acid translation of APEX-1 is shown on page 42973-158. These notebook records evidence conception and actual reduction to practice of the complete invention prior to December 9, 1999.

5. The materials submitted herewith establish that the invention as claimed was completed, i.e. conceived and reduced to practice, at a date prior to December 9, 1999, the publication date of the '088 publication.

6. This declaration is submitted in a response to a Final Office Action dated February 25, 2003 and is therefore believed to be timely filed.

7. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



DATED: 18 August 2003

Gary C. Starling
Gary C. Starling

DATED: _____

Joshua N. Finger

BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE



BRISTOL-MYERS SQUIBB

NOTEBOOK N^o 42973Assigned to Joshua N. Fungie

Department Name _____

Department Number _____

Date Assigned . . . _____

Date Completed _____

Pages Completed from 001 to 200

Continued from Notebook Number _____

Continued in Notebook Number _____

This notebook cannot be transferred to another person

TABLE OF CONTENTS

PROJECT OR EXPERIMENT NO.	PRODUCT OR SUBSTANCE	STUDY PERFORMED OR OBJECTIVE	PA
		Construction of Dendritic substrate plate	09
		Hybridization of Southern	091
		Colonies for Streptococcus - Meningitis	09
		"	09
		cDNA synthesis	09
		Adoptive transfer	09
		Dendritic clones	09
		"	09
		"	091
		Dendritic clone hybridization	09
		"	10
		"	10
		BLANK	10
DCS4 (Apex 1)		DCS4 (clone #4) and Clone # B2 isolation	10
		"	10
		"	10
		BLANK Southern blot	10
		BLANK	10
		BLANK	10
		RNA isolation, THP1, NIH3T3, BJAB	10
		Northern hybrid of cell lines	11
		"	11
		DCS4 3'-RACE	11
		"	11
		"	11
		Northern blot of cell lines	11
		DCS4 3'-RACE	11
		"	11
		DCS4 northern analysis - MEN's	11

TABLE OF CONTENTS

PROJECT OR EXPERIMENT NO	PRODUCT OR SUBSTANCE	STUDY PERFORMANCE OR OBJECTIVE	PAGES
	DCS4 MTN blots		119
	"		120
	DCS4 3'-RACE cloning		121
	" transformation		122
	"		123
	RT-PCR in cell lines - DCS4		124
	"		125
	"		126
	Full-length cloning DCS4		127
	RT-PCR using INF6/7 - DCS4		128
	"		129
WPT61 Library	RNA isolation from activated PBSTs (P44)		130
	cDNA synthesis - WPT61 library		131
	"		132
	"		133
	RsaI digestion - WPT61 library		134
	"		135
	Hybridization		
	Adapter ligations - WPT61 library		136
	"		137
	"		138
	DCS4 RT-PCR - cell lines		139
	"		140
	Ligation efficiency - WPT61 library		141
	FLDCS4 miniprep		142
	Genomic Southern		143
	DCS4 INF6/7 probe prep		144
	"		145
	Genomic PCR using primer pairs		146
	"		147

DATE

PROJ. NO.

EXPT. NO.

SUBJECT Isolation of Clone #4 and Clone #92

PURPOSE: To isolate the cDNA inserts from clone #4 and clone #92 from plasmid DNA for use as probes.

5

Materials and Methods


a) Clone #4	0.5ul
Restrict III	0.1ul
EcoRI	1ul
H ₂ O	3ul
	10ul

10

b) Clone #92	19ul
Restrict III	3ul
Pst I	1.5ul
Hind III	1.5ul
H ₂ O	5.0ul
	30.0ul

15

20

RESULTS:

Lane 1: No Marker
 Lane 2: Clone #4
 Lane 3: ~~Blank~~ BLANK LANE
 Lane 4: BLANK LANE
 Lane 5: Clone #92
 Lane 6: Clone #92

25

30

Discussion: Clone #4 must have a mutated EcoRI site, cut again with Hind III and Pst I, to clone and isolate clone #92 insert and analyze.

35

END

SIGNED

DATE

WITNESSED AND UNDERSTOOD BY:

DATE

CROSS-REFERENCES:

DATE

J. NO

EXPT NO

SUBJECT

Reclat of Clone #4 using Pst I and Hind III

Purpose To drop out insert of clone #4 using enzymes other than EcoRI

5

Materials and Methods

10

Clone #4	1.5 μ l
Restr II	3 μ l
Pst I	1.5 μ l
Hind III	1.5 μ l
H ₂ O	9.0 μ l
	30.0 μ l

15

Results

Lane 1 (M) marker
Lane 2 HIP digest of DSS4
Lane 3 HIP digest of DSS4

20

25

Gel purify this fragment

2nd fragment

Discussion

30

Just as I suspected DSS4 clone has a mutated EcoRI site as shown by inability of EcoRI to cut out insert (42973-103, lane 2). However, Hind III and Pst I dropped out two fragments. One fragment approximately 400 bp in size will be gel purified and used as a probe (HP400). The 2nd fragment is approximately 80-90 bp and will go into the trash.

35

END

SIGNED

DATE

WITNESSED AND UNDERSTOOD BY:

DATE

CROSS REFERENCES:

[Signature]

[Signature] Habbe

DATE: _____ VOL. NO. _____ EXPT. NO. _____

SUBJECT: Gel purification of clones # 2 & 4

Purpose To get purify both clones isolated from Drosophila cell suspension library for use as probes in further exp.

5

Materials & Methods

See protocols from Qiagen's Spin Handbook

"Qiagen's gel extraction kit" (Qiagen Cat # 24704)

10

RESULTS

abs 260.0 nm	abs 280.0 nm	bkg abs 320.0 nm	260.0 nm 280.0 nm	280.0 nm 260.0 nm	Protein ug/ml	Nucleic Acid ug/ml
1) 0.0048	0.0027	0.0002	1.8457	0.5418	0.0025	23.1278
2) 0.0109	0.0045	-0.0006	2.2434	0.4457	0.0051	57.5225
3) 0.3912	0.2485	0.0023	1.5793	0.6332	0.2463	1944.6359
4) 0.4535	0.2929	0.0039	1.5558	0.6428	0.2890	2248.1201

$$[C] = \frac{(A_{260} \times (50^{25}/ml) - D)}{1000} = \frac{0.9}{1}$$

1) DSS4

25

$$(0.0048 \times 50^{25}/ml \times 25) / 1000 = \boxed{6^{25}/ml}$$

2) DSS02

$$(0.0109 \times 50^{25}/ml \times 25) / 1000 = \boxed{13^{25}/ml}$$

3) DSS4.1
DSS4

$$(0.3912 \times 50^{25}/ml \times 200) / 1000 = \boxed{3.9^{25}/ml}$$

$$4) DSS4.2 (0.4535 \times 50^{25}/ml \times 200) / 1000 = \boxed{4.5^{25}/ml}$$

DISCUSSION:

35

NONE

END

SIGNED

DATE

WITNESSED AND
UNDERSTOOD BY:

DATE

CROSS REFERENCES:

John M. Jiri

Hask

DATE

NO.

EXPT NO.

SUBJECT South... Hybridization to confirm expression of PSSM in subcloned library

PURPOSE: To analyze the presence of PSSM in D12 cDNA, THP1 cDNA and D12-THP1 subcloned cDNA. To also see if other housekeeping genes such as GAPDH were expressed in the subcloned cDNA library.

5

Materials and Methods:

10µg of each cDNA was loaded into each well

10

and run at 70V for 3 hours.

DNA was stained (see gel photo)

	abs 260.0 nm	abs 280.0 nm	bkg abs 320.0 nm	260.0 nm 280.0 nm	280.0 nm 260.0 nm	Protein ug/ml	Nucleic Acid ug/ml
1)	0.6093	0.4039	0.0198	1.5350	0.6515	0.3840	2947.4448
2)	0.9419	0.5982	0.0306	1.6055	0.6229	0.5676	4556.4517
3)	0.2023	0.1188	0.0005	1.7056	0.5863	0.1183	1008.9186

20

$$CJ = Abs \times 50^{1/ml} \times 10 = \mu g/ml$$

1) D12 cDNA:

$$0.4039 \times 50^{1/ml} \times 50 = 1.5 \mu g/ml$$

25

2) THP1 cDNA: $0.9419 \times 50^{1/ml} \times 50 = 2.4 \mu g/ml$

3) D12-THP1 subcloned cDNA: $0.2023 \times 50^{1/ml} \times 50 = 0.5 \mu g/ml$

30

AT Lane 1: D12 cDNA

Lane 2: THP1 cDNA

Lane 3: D12-THP1 subcloned cDNA

35

SIGNED

DATE

WITNESSED AND
UNDERSTOOD BY

DATE

CROSS REFERENCES:

DATE: _____

REQ. NO. _____

EXPT. NO. _____

SUBJECT 3' RACE using DSS4 gene specific primers and RT, RT-PCR

Purpose: To amplify the remaining 3' end of the unknown DSS4 gene which shows homology to CDB4

5

Materials and Methods

1) cDNA synthesis in Dendritic, THP1, and T-lymphocyte cells

10

poly A⁺ RNA 2ulPrimer Q₁(5'NF3) 1uldH₂O (DEPC) 9ul12ul

• Incubate @ 70°C for 10 min. Then 1 min.

15

Add to RNA/primer mix.

10x PCR Buffer 2ul25mM MgCl₂ 1ul10mM dNTP's 2ul

20

0.1M DTT 2ul7ul

A) Incubate @ 42°C 5min

Add 1ul Superscript II RT

25

Incubate @ 42°C 1 hour

Stop Rxn by 70°C incubation

Add 1ul RNase H

Store @ -20°C

30

continued 113

35


SIGNED

DATE

WITNESSED AND UNDERSTOOD BY:

DATE

CROSS REFERENCES:

DATE _____ PROJ. NO. _____ EXPT. NO. _____

SUBJECT Control Com 42923-112Combination Com 42923-112

2) Primary PCR using JNF1 and Q(JNF4)

5

JNF1 1 μ lJNF4 1 μ ldNTP's 1 μ l10x PCR Buffer 5 μ l

10

T₅₀cDNA 1 μ ldH₂O 39 μ l50x cDNA Amplification mix 1 μ l50 μ l

15

PCR parameters: 94°C 1 min 1 cycle

94°C 1 min

57°C 1 min

72°C 2 min

72°C 2 min

25 cycles

1 cycle

20

3) Secondary PCR using JNF2 and Q-(JNF5)

JNF2 1 μ lJNF5 1 μ l

25

dNTP's 1 μ l10x PCR Buffer 5 μ l1/50 dilution of PCR 1 μ ldH₂O 39 μ l50x Polymerase mix 1 μ l

30

50 μ l

PCR parameters: same as Primary PCR

Control to 114

35

SIGNED

John N. Jr.

DATE

WITNESSED AND
UNDERSTOOD BY:*Heble*

DATE

CROSS REFERENCES:

REF-15

1 2 3 4 5 6 7 8

5

10

15

Discussion

20

25

Layers 2, 3, 4 are primary PIR using gips (JNFI) and prime. Col. (JNFI)
 The seems to be background pattern. Either extension base of 2 min. was
 too long or Tm of annealing was lower. Secondary PIR using gips (JNFI)
 and prime Q₂ (JNFI) reduced background considerably, but contains several
 bands which are not reproducible (Layers 2, 6, 7). Continue with R₂ (JNFI)
 experiment, starting with 1/52 dilution of 1st PIR, but increase Tm to
 58°C and reduce extension to 1 min (since most prominent band in
 JNFI line is around 900 bp).

END

30

35

SIGNED

CROSS REFERENCES:

DATE

WITNESSED AND UNDERSTOOD BY

DATE

J. N. Jiz

HABR

DO NOT WRITE IN THIS MARGIN

DATE: PROJ: EXPT. NO.

SUBJECT: Cloning of Full length DCS4 cDNA including 3' UTR.

PURPOSE: To isolate the full length DCS4 cDNA of size approximately 2.6 kb from 50 µl of PCR mixture.

5 Materials and Methods


<u>PCR</u>		<u>PCR parameters</u>
10	EP (Eppendorf)	2.5 µl
	RP (TRIzol)	1.0 µl
	dNTPs	1.0 µl
	10x PCR Buffer	5.0 µl
	Admix Polymerase	1.0 µl
	H ₂ O	38.5 µl
15	Reaction mix	1.0 µl
		50.0 µl
		94°C 1 min
		94°C 1 min
		57°C 1 min
		72°C 2.5 min
		72°C 10 min

Run all 50 µl on 1.2% agarose gel.

Isolate 2.5 kb band using gel extraction kit (Qiagen)

Run on 2.0% gel; check conc.

20



Lane 1: 10 marker

Lane 2: 1 µl isolated PCR fragment

Lane 3: 3 µl isolated PCR fragment

Lane 4: 2 µl 10 marker (1.3 kb band = 10 ng)

Lane 5: 4 µl 10 marker (1.3 kb band = 32 ng)

25

Conc. of isolated fragment is 100 : = 2 ng/µl

Ligate fragment into TA cloning vector

30

Result: Amount of 2.5 kb fragment isolated is very low, but I ligated any just to try and isolate a clone.

Discussion: No discussion yet, wait until transformation.

35

SIGNED

CROSS REFERENCES:

[Signature]

DATE

WITNESSED AND UNDERSTOOD BY:

[Signature]

DATE

DATE: _____ PROJ. NO. _____ EXPT. NO. _____

SUBJECT RT-PCR using primers TNF α and TNF β

Purpose: To optimize parameters for RT-PCR using primers TNF α and TNF β to get one band at 600 bp amplified in cell lines which express TNF α gene.

5 Materials and Methods

1) 1st PCR: TNF α primers 1 μ l DNA's used:
 TNF β primers 1 μ l a) Dendritic
 dNTP's 1 μ l b) LPS A549 T cell
 10x PCR Buffer 5 μ l c) THP1
 Adenine Polymerase 1 μ l
 dH₂O 40 μ l
 DNA 1 μ l
 50 μ l

Parameters: 94°C 1min
 94°C 1min
 63°C 1min } 30 cycles
 72°C 45sec
 72°C 1min

Lane 1: A1 ϕ min
 Lane 2: Dendritic
 Lane 3: LPS A549 T
 Lane 4: THP1

RESULT 1: 600 bp band was visible, but a high background was present in reactions. Reduce PCR with elevation of annealing temp to 65°C, in order to reduce background.

2) 2nd PCR: TNF α primers 0.5 μ l cDNA's used:
 TNF β primers 0.5 μ l a) LPS A549 T
 dNTP's 0.5 μ l b) THP1
 10x PCR Buffer 2.5 μ l
 Adenine Polymerase 0.5 μ l
 Parameters: 94°C 1min dH₂O 20.0 μ l
 94°C 1min cDNA 0.5 μ l
 63°C 1min } 25 cycles
 72°C 45sec
 72°C 1min 25.0 μ l

culture 42973-124

SIGNED

DATE

WITNESSED AND UNDERSTOOD BY:

DATE

CROSS REFERENCES:

DO NOT WRITE IN THIS MARGIN

DATE

PROJ.

EXPT. NO.

SUBJECT

Concord 42973-128

Result 2: Significant reduction of background, providing excellent inhibition of non-specific binding in LPS Non-T cells and no signal in THP1 as found earlier in page 42973-125.

5

Discussion: This experiment was done to optimize PCR parameters for RT-PCR of immunological cell lines in order to identify which cell type express the DCS4 transcript. As shown above, LPS Non-T cells express DCS4, but THP1 does not. The significance of lack of expression in THP1 - RNA shows the original subtraction experiment suggested cDNA's expressed differentially between GM-CSF/IL-4 differentiated human monocytes and THP1 monocytes. This is also proven by expression of DCS4 in dendritic cDNA. Report PCR for all available cell lines.

10

15

20

25

30

35

END

SIGNED

DATE

WITNESSED AND UNDERSTOOD BY:

DATE

CROSS REFERENCES:

DATE: _____ JI. NO. _____ EXPT. NO. _____

SUBJECT Full length cDNA sequence and a.a. translation Co-DCS4

		GGAAAGTGGCTTCATTTCAGTGGCTGACTTCCAGAGAGCAAT	41
		ATGGCTGGTTCCCAACATGCCTCACCTCATCTATATCTTTGGCAGCTCACAGGGTCA	101
		<u>M A G S P T C L T L I Y I L W O L T G S</u>	20
		GCAGCTCTGGACCCGTGAAAGAGCTGGTCCGTTCCGTTGGTGGGGCCGTGACTTTCCTCC	161
		<u>A A S G P V K E L V G S V G G A V T F P</u>	40
		CTGAAGTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAACCCCTCTT	221
		<u>L K S K V K Q V D S I V W T F N T T P L</u>	60
5		GTCACCATAACAGCCAGAAGGGGGCACTATCATAGTGACCCAAATCGTAATAGGGAGAGA	281
		<u>V T I Q P E G G T I I V T Q N R N R E R</u>	80
		GTAGACTTCCAGATGGAGGCTACTCCCTGAAGCTCAGCAAACTGAAGAAGAATGACTCA	341
		<u>V D F P D G G Y S L K L S K L K K E D S</u>	100
		GGGATCTACTATGTGGGGATATACAGCTCATCACTCCAGCAGCCCTCCACCCAGGAGTAC	401
		<u>G I Y Y V G I Y S S S L Q Q P S T Q E Y</u>	120
		GTGCTGCATGTCTACGAGCACCTGTCAAAGCCTAAAGTCACCATGGGTCTGCAGAGCAAT	461
		<u>V L H V Y E H L S K P K V T M G L Q S N</u>	140
10		AAGAATGGCACCTGTGTGACCAATCTGACATGCTGCATGGAACATGGGGAAGAGGATGTG	521
		<u>R N G T C V T N L T C C H E H G E E D V</u>	160
		ATTTATACCTGGAAGGCCCTGGGGCAAGCAGCCAAATGAGTCCATAATGGGTCCATCTC	581
		<u>I Y T W K A L G Q A A N E S H N G S I L</u>	180
		CCCATCTCTGGAGATGGGGAGAAAGTGATATGACCTTCATCTGCGTTGCCAGGAACCTC	641
		<u>P I S W R W G E S D N T F I C V A R N P</u>	200
		GTCAGCAGAACTCTCAAGCCCCATCTTGGCAGGAAGCTCTGTGAAGGTGCTGCTGAT	701
		<u>V S R E A P E S P I L A R K L C E G A A D</u>	220
15		GACCCAGATTCTCTCAAGGCTCTCTGCTCTCTGTTGGTGGCCCTCTCTGCTCAGTCTC	761
		<u>D P D S S H V L L C L L L V P L L L S L</u>	240
		TTTGTAAGTGGCTATTTCTTTGCTTTCTGAAGAGAGAGAGACAAGAAGTACATTGAA	821
		<u>F V L G L P L W F L K R E R Q E E Y I E</u>	260
		GAGAAGAAGAGAGTGGACATTTGTGGGAAACTCTTAACATATGCCCCCATTTCTGGAGAG	881
		<u>E K K R V D I C R E T P N I C P H S G E</u>	280
		AACACAGAGTACGACACAATCCCTCACACTAATAGAACAATCTAAAGGAAGATCCAGCA	941
		<u>N T E Y D T I P H T N R T I L K E D P A</u>	300
20		AATACGGTTTACTCCACTGTGGAAATACCGAAAAGATGGAAAATCCCCACTCACTGCTC	1001
		<u>N T V Y S T V E I P K K M E N P H S L L</u>	320
		ACGATGCCAGACACACCAAGGCTATTGCGCTATGAGAATGTTATCTAGACAGCAGTGCAC	1061
		<u>T H P D T P R L F A Y E N V I</u>	335
		TCCCCAAGTCTCTGCTCAAAAAAACAATTTCTCGGCCCAAGAAAACAATCAGAAGA	1121
		<u>ATTCAGTATTTGACTAGAAACATCAAGGAAGAATGAAGAACGTTGACTTTTTTCCAGGA</u>	1181
		<u>TAAATTATCTCTGATGCTTCTTTAGATTTAAGAGTTGTAATTCATCCACTGCTGAGAA</u>	1241
25		<u>ATCTCTCAAAACCCAGAAGGTTTAACTCACTTCATCCCAAAATGGGATTGTGAATGTCAG</u>	1301
		<u>CAAAACATAAAAAAGTGCTTAGAAGTATTCCTATAGAAATGTAAATGCAAGGTCACACA</u>	1361
		<u>TATTAATGACAGCCTGTTGTATTAATGATGGCTCCAGGTCAGTGTCTGGAGTTTCATTC</u>	1421
		<u>ATCCCAAGGCTTGGATGTCAAGGATATACCAAGAGTCTTCTACCAGGAGGGCAAGAAGA</u>	1481
		<u>CCAAACAGACAGACAAGTCCAGCAGAAGCAGATGCACCTGACAAAATGGATGTATTAA</u>	1541
		<u>TTGGCTCTATAAATATGTGCCAGCACTATGCTGAGCTTACACTAATTTGGTCAGACGTG</u>	1601
		<u>CTGTCTGCTCATGAATTTGGCTCCAAATGAATGAATCACTTTCAAGGAGTGTAGC</u>	1661
		<u>AGGCTGACCAAGATTTCCAGAGGGCCAGGTGTGGATCCACAGGACTTGAAGGTCAAAG</u>	1721
		<u>TTCAACAGATGAAGAATCAAGGTAGCTGACCATGTTTGGCAGATACTATAATGGAGACA</u>	1781
		<u>CAGAGTGTGCATGGCCCAAGGACAAGGACTCCAGCCAGCTTCATTTATGCACTTGTG</u>	1841
		<u>CTGCAAAAGAAAAGTCTAGGTTTAAAGGCTGTGCCAGAACCCATCCCAATAAGAGACCG</u>	1901
30		<u>AGTCTGAAGTCACATTTGTAATCTAGTGTAGGAGACTTGGAGTCAGGCAGTGAGACTGT</u>	1961
		<u>GGGGCAGGGGGGCGAGTGGTACTTGTAAACCTTTAAAGATGGTTAATTCATTCAATAGA</u>	2021
		<u>TATTTATTAAGAACCTACTATGCGGCCCCGGCATGGTGGCTCACACCTGTAATCCAGCAC</u>	2081
		<u>TTTGGGAGGCCAAGGTGGGTGGGTCACTGAGGTCAAGGAGTCAAGACCAGCCTGGCCAA</u>	2141
		<u>CATGGTGAACCCCACTCTACTAAAGATCAAAATTTGCTGAGCGTGGTGGTGTGCACCT</u>	2201
		<u>GTATCCAGCTACTCGAGAGGGCAAGGCAAGGATCGCTTGAACCTGGAGGTGAGGTG</u>	2261
		<u>CAGTGAGCTGAGATGGCACCACCTGCACCTCCGGCTAGGCAACGAGAGCAAACTCCAATA</u>	2321
		<u>CAACAAACAAACAAACACCTGTGCTAGGTCACTCTGGCAGGTAAGATGAACATCCCTAC</u>	2381
		<u>CAACACAGAGCTCACCATCTCTTATACTTAAGTGAATAACATGGGAAAGGGGAAAGGGGA</u>	2441
		<u>ATGGCTGCTTTTGATATGTTCCCTGACGCATATCTTGAATGGAGACCTCCCTACCAAGTG</u>	2501
		<u>ATGAAAGTGTGAAAACTTAATAACAAATGCTTGTGGGCAAGAAATGGGATTGAGGATT</u>	2561
35		<u>ATCTTCTCTCAGAAAGGCATTGTGAAGGAATTGAGCCAGATCTCTCTCCCTACTGCAAAA</u>	2621
		<u>CCCTATTGTAGTAAAAAGTCTTCTTACTATCTTAATAAAACAGATATTGTGAGATTCA</u>	2681
		<u>CATAAAAAAAAAAAAAAAAAAAAA</u>	

Word Document
FLDCS4.doc

SIGNED

DATE

WITNESSED AND
UNDERSTOOD BY:

DATE

CROSS REFERENCES: